Rheumatology 2001; 40: 623-630
© 2001 British Society for Rheumatology
Original Papers |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint
1 Department of Orthopaedics and Trauma, The University of Adelaide and The Royal Adelaide Hospital, Adelaide 5000, SA, Australia
Objective. This study investigated the involvement of the recently identified regulators of osteoclast formation RANKL [receptor activator of nuclear factor kappaB (RANK) ligand, osteoclast differentiation factor, TRANCE, osteoprotegerin ligand] and its natural inhibitor, osteoprotegerin (OPG), in the bone erosion of rheumatoid arthritis (RA).
Methods. mRNA was extracted from cells isolated from the pannus and synovial membrane regions of joints of 11 RA patients. Semiquantitative reverse transcription–polymerase chain reaction was carried out, and the isolated cells were also cultured to determine their ability to form osteoclasts.
Results. mRNAs encoding RANKL, RANK, OPG and macrophage-colony stimulating factor were expressed by cells isolated from RA joints. In addition, mRNA encoding for tumour necrosis factor apoptosis-inducing ligand and the osteoclast markers tartrate-resistant acid phosphatase and calcitonin receptor were also often expressed. Osteoclasts capable of forming resorption lacunae were generated from cells in the RA joints. At 50 ng/ml, recombinant OPG completely inhibited the resorptive activity of these cells. There was a significant correlation between the ratio of RANKL mRNA to OPG mRNA and the number of resorption pits produced (P = 0.028).
Conclusion. These data suggest that RANKL is an essential factor for osteoclast formation by cells in the rheumatic joint and that OPG may prevent the bone erosion seen in RA joints.
KEY WORDS: Bone, Rheumatoid arthritis, Joint damage, Cytokines, Osteoclasts, Osteoprotegerin.
Correspondence to: D. R. Haynes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. NARDUCCI, R. BAREGGI, and V. NICOLIN Interaction of Human Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Osteoprotegerin Could Contribute to Enhancement of the Erosive Processes Induced by Human Synovial Cells J Rheumatol, August 1, 2009; 36(8): 1837 - 1839. [Full Text] [PDF]
|
|
|
|
 |
|
 S.Y. Fukada, T.A. Silva, I.F. Saconato, G.P. Garlet, M.J. Avila-Campos, J.S. Silva, and F.Q. Cunha iNOS -derived Nitric Oxide Modulates Infection-stimulated Bone Loss Journal of Dental Research, December 1, 2008; 87(12): 1155 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Pettit, N. C. Walsh, C. Manning, S. R. Goldring, and E. M. Gravallese RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis Rheumatology, September 1, 2006; 45(9): 1068 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kishimoto, S. Fukumoto, S. Nishihara, H. Mizumura, K. Hirai, and R. Teshima Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis Rheumatology, December 1, 2004; 43(12): 1496 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O'Gradaigh and J. E. Compston T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion Rheumatology, February 1, 2004; 43(2): 122 - 130. [Full Text] [PDF]
|
|
|
|
 |
|
 R Rau, O Sander, and S Wassenberg Erosion healing in rheumatoid arthritis after anakinra treatment Ann Rheum Dis, July 1, 2003; 62(7): 671 - 673. [Full Text] [PDF]
|
|
|
|
|
|
M D Smith, E Barg, H Weedon, V Papengelis, T Smeets, P P Tak, M Kraan, M Coleman, and M J Ahern Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints Ann Rheum Dis, April 1, 2003; 62(4): 303 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Varsani, A. Patel, Y. van Kooyk, P. Woo, and L. R. Wedderburn Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-{kappa}B (RANK) Rheumatology, April 1, 2003; 42(4): 583 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Haynes, E. Barg, T. N. Crotti, C. Holding, H. Weedon, G. J. Atkins, A. Zannetino, M. J. Ahern, M. Coleman, P. J. Roberts-Thomson, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls Rheumatology, January 1, 2003; 42(1): 123 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T N Crotti, M D Smith, H Weedon, M J Ahern, D M Findlay, M Kraan, P P Tak, and D R Haynes Receptor activator NF-{kappa}B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis Ann Rheum Dis, December 1, 2002; 61(12): 1047 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D H. Jones, Y-Y Kong, and J M Penninger Role of RANKL and RANK in bone loss and arthritis Ann Rheum Dis, November 1, 2002; 61(90002): ii32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E M Gravallese Bone destruction in arthritis Ann Rheum Dis, November 1, 2002; 61(90002): ii84 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Danks, A Sabokbar, R Gundle, and N A Athanasou Synovial macrophage-osteoclast differentiation in inflammatory arthritis Ann Rheum Dis, October 1, 2002; 61(10): 916 - 921. [Abstract] [Full Text] [PDF]
|
|